Novo Nordisk ADR (NYSE:NVO) currently has a daily average trading volume of 9.63M but it saw 8980287 shares traded in last market. With a market cap of 233.81B USD, the company’s current market price of $69.46 came rising about 1.25 while comparing to the previous closing price of $68.60. In past 52 weeks, the stock remained buoying in the range of price level as high as $148.15 and as low as $57.00.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BMO Capital Markets which downgraded the stock as “Market Perform” in its note to investors issued on April 17, 2025, recommending a price target of $64 for it.
Over the week, NVO’s stock price is moving 1.85% up while it is 6.60% when we observe its performance for the past one month. Year-to-date it is -19.25% down and over the past year, the stock is showing a downside performance of -48.94%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of 5.92 while estimate for next year EPS is 26.09. In next quarter, company is expected to be making quarterly sales of $83B as analysts are expecting the sales for current fiscal year at $334.46B and seeing the company making $385.26B in sales next year. Moreover, analysts are in estimates of $77.51B for current-quarter revenue.
Currently, Novo Nordisk ADR’s total number of outstanding shares is 3.37B with 0.01% of that held by the insiders while 9.86% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 44.25% and return on equity (ROE) at 87.53%. It has a price to earnings ratio (P/E ratio) of 20.60 while having a 14.71 of forward P/E ratio. Stock’s beta reads 0.65. Stock has a price to book (P/B) ratio of 15.38 while price to sale or P/S ratio amounts to 5.36. Its return on asset (ROA) is 26.37% on average.
